Alan D. Wickenden
Icagen Inc.
Suite 460
4222 Emperor Boulevard
Durham
USA
Name/email consistency: high
- K(+) channels as therapeutic drug targets. Wickenden, A. Pharmacol. Ther. (2002)
- Potassium channels as anti-epileptic drug targets. Wickenden, A.D. Neuropharmacology (2002)
- Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Wickenden, A.D., Zou, A., Wagoner, P.K., Jegla, T. Br. J. Pharmacol. (2001)
- Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Wickenden, A.D., Yu, W., Zou, A., Jegla, T., Wagoner, P.K. Mol. Pharmacol. (2000)









